An unmet need exists for patients with relapsed/refractory (R/R) follicular lymphoma (FL) and
high-risk disease features, such as progression of disease within 24 months (POD24) from …

CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has had a dramatic impact
on the natural history and survival of patients with high‐risk B‐cell non‐Hodgkin lymphoma …

Indolent B-cell non-Hodgkin lymphomas (B-NHL), chronic lymphocytic leukemia (CLL), and
mantle cell lymphoma (MCL) are widely treatable but typically incurable with conventional …

Follicular lymphoma (FL) is a generally incurable malignancy that originates from
developmentally blocked germinal center (GC) B cells residing, primarily, within lymph …

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL).
Significant unmet need remains for patients with relapsed/refractory (R/R) FL after≥ 3 lines …

Background A standard of care and optimal duration of therapy have not been established
for patients with multiply relapsed or refractory follicular lymphoma. The aim of this study was …

Background Follicular lymphoma (FL) is characterized by an incurable course that frequently
necessitates multiple lines of treatment. While a range of new approaches have broadened …

Objectives The results of a recent single-arm trial (ZUMA-5) of axicabtagene ciloleucel (axi-
cel) for relapsed/refractory (r/r) follicular lymphoma (FL) demonstrated high rates of durable …

Follicular lymphoma is the most common indolent lymphoma accounting for approximately
20%–25% of all new non‐Hodgkin lymphoma diagnoses in western countries. Whilst …

Indolent lymphomas (iNHL) are mature small B-cell neoplasms that include but are not
limited to follicular lymphoma (FL), marginal zone lymphoma (MZL) and lymphoplasmocytic …